Mindray Partners with Epiphany - Analyst Blog
07 Dicembre 2011 - 2:00PM
Zacks
Mindray Medical
International Limited (MR), a leading Chinese medical
device manufacturer, recently revealed a partnership with Epiphany
Cardiography Products of Midlothian, Virginia. Per their
collaboration, which is based in North America, Mindray’s 12-lead
cardiac monitoring information will be intertwined with Epiphany’s
user-friendly and web browser-based Cardio Server application. This
application can accept, manage and transmit test results from more
than 100 devices to Electronic Health Records (“EHR”).
Epiphany, founded in 2004, manages
with ease the gathering and handling of diagnostic test results.
Its products are used by 330 hospitals globally.
The 12-lead cardiac monitoring data
from Mindray encompasses continuous 12-lead arrhythmia analysis. It
permits users to develop an image of the victim’s heart before they
demonstrate ailments or as they recuperate. The Cardio Server
allows users to obtain, manage and print out high-class 12-lead
ECGs from any location where they possess a web browser. ECGs are
also available from devices such as iPhone, iPad and Android.
According to Mindray, the open
architecture of the Cardio Server from Epiphany gives its clients
the head start they desire in access to information and integration
of devices. Thus, interoperability is viewed as a critical element
of success. The purpose of the partnership is to derive synergy
from the enterprise-sized offerings of Cardio Server with modern
monitoring know-how from Mindray.
Mindray is a bellwether in the
Chinese MedTech industry with a solid international presence. A key
distinction with domestic competitors is that the majority of
Mindray’s products have CE Mark and/or Food and Drug Administration
(“FDA”) clearance.
Mindray maintains a decent product
pipeline and brings out several new products each year. New
products contribute in a major way to Mindray’s revenues.
The company has entered the premium
segment globally, where its competitive advantage is still unclear.
Also, on the negative side, health care reform in China and the
U.S., may reduce demand for Mindray’s products. Competition is
fierce and leads to price erosion over time.
Mindray’s competitors, in different
niche segments, include General Electric (GE),
Philips (PHG) and Siemens (SI).
Our Neutral recommendation is supported by a short-term Zacks #3
Rank (Hold).
GENL ELECTRIC (GE): Free Stock Analysis Report
MINDRAY MEDICAL (MR): Free Stock Analysis Report
KONINKLIJKE PHL (PHG): Free Stock Analysis Report
SIEMENS AG-ADR (SI): Free Stock Analysis Report
Zacks Investment Research
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Lug 2023 a Lug 2024